Center for Cognitive and Memory Disorders
Assistant Professor Clinical
College of Medicine
Department of Neurology
395 W. 12th Ave.
6th floor, R 618
Columbus, OH 43210
- Alzheimer’s disease and dementia, cognitive disorders in the spectrum of neurological and neuropsychiatric conditions
- Behavioral disturbances in the spectrum of dementias
- Mild cognitive impairment and early dementia
- SAGE (Self-Administered Gerocognitive Examination)
- Pharmacogenomics in dementia
- Functional imaging in dementia
Research Techniques: Multi-site collaborative research studies for development of new medications for dementias; gene expression analysis; analysis of genetic polymorphisms; clinical studies; cognitive evaluation of patients to monitor early signs of a neurodegenerative process, progression and management over time; functional imaging biomarkers; CSF analysis; and volumetric MRI studies.
- 2017: PI: A phase 2, double-blind, randomized, placebo-controlled study of Nelotanserrin versus placebo in patients with Lewy body dementia (LBD) experiencing REM sleep behavior disorder (RBD). RVT-102-2002. Axovant Sciences, Ltd.
- 2017:PI:A phase 2, double-blind, randomized, placebo-controlled crossover study evaluating the effect of RVT-101 on gait and balance in subjects with Alzheimer’s Disease, Dementia with Lewy Bodies, or Parkinson’s Disease Dementia. RVT-101-2003.
- 2017:PI: An open-label study of nelotanserin in patients with Lewy body Dementia who have frequent visual hallucinations or REM sleep behaviors. RVT-102-2003. Axovant.
- 2017: PI: A phase 2, double-blind, randomized, placebo-controlled cross over study of Nelotanserin versus placebo in Lewy body dementia (LBD) subjects experiencing visual hallucinations (VH). RVT-102-2001. Axovant Sciences, Ltd.
- 2017:PI: A Long Term Extension of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies(DLB). RVT-101-2002. Sponsor Axovant. Amendment. Related Protocol: 2016W0140
Background: In 2004, she joined the faculty at The Ohio State University Department of Neurology, Neurobehavior Division, and she has served as the director of clinical operations of the Neurobehavior Division since 2014. Dr. Kataki is a board certified neurologist, with subspecialty training in Alzheimer’s disease and dementia, a clinical researcher, a physician’s educator and an expert in the field of cognitive disorders and neurodegenerative diseases.
MD: Medical School of Athens, National and Kapodistrian University
PhD: National and Kapodistrian University, Department of Neurology
Resident: Neurology, National and Kapodistrian University of Athens, Eginition Hospital
Intern: University of Texas-Houston Medical School
Resident: Neurology, Baylor College of Medicine
Research Associate: Functional Neurosurgery, University of Texas, Health Science Center, Department of Neurosurgery
Fellow: Alzheimer’s Disease and Dementia, Baylor College of Medicine, Department of Neurology, and the Alzheimer’s Disease Research Center
Fellow: Neurobehavioral Neurology: Section of Neurobehavioral Neurology and the Houston VAMC Cognitive Disorders Center
- Visiting Resident, Department of Neurology, Alzheimer’s Disease Research Center, Baylor College of Medicine, Houston Texas, November 1993 - May 1994, sponsored by National university of Athens, Department of Neurology
- Travel Award, 6th International Conference on Alzheimer’s Disease and Related Disorders. Amsterdam Rai 18-23 July 1998
- Loren Rolak Award for 2003 for Best Online Case Publication in Neurology, Baylor College of Medicine, Department of Neurology
- Who’s Who National Registry, 2004-2005
- Who’s Who Madison Honorary Registry for Executive and Professionals, 2009-2011
- Who’s Who Madison Honorary Registry for VIP Executive and Professionals 2009-2011
- International Association of Health Care Professionals, “The Leading Physicians of the World,” Publication 2012-2013-2014 Recipient of the Neurosciences Excellence Award 2012, Ohio State Wexner Medical Center, Department of Neurology